NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Drug Manufacturers - Specialty & Generic · USD

cbdMD, Inc. (YCBD) Stock Analysis

cbdMD, Inc. (YCBD) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

YCBD

$0.38

−$0.01 (−2.17%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare YCBD with… →

YCBD Key Statistics

As of Oct 21, 2026
Trading
Open
$0.38
Previous Close
$0.39
Day's Range
0.37–0.39
52-Week Range
0.33–2.56
Volume
73.52K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.25
Valuation
Market Cap
$4.25M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.20
Financials (FY)
Revenue (FY)
$19.19M−1.50%
Net Income (FY)
−$2.04M
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.80%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.21M
1-Year Return
−64.25%
Dividend and dates
Avg Volume
406.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, YCBD closed at $0.38, −64.25% over 1 year.

cbdMD, Inc. (YCBD) has a market capitalization of $4.25M.

In fiscal 2025, YCBD reported revenue of $19.19M.

YCBD Stock Return by Calendar Year

cbdMD, Inc. (YCBD) return since Nov 2017: what $10,000 became

1 year
$10,000 $3,575
−64.25%
5 years
$10,000 $5
−99.95%
Since Nov 2017
$10,000 $2
−99.98%

If you had invested $10,000 in cbdMD, Inc. (YCBD) at the close on November 17, 2017, the earliest close on record here, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −61.72% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.93%
2025−55.00%
2024−63.94%
2023−89.82%
2022−78.98%
2021−63.39%
2020+30.53%
2019−26.86%
2018−28.97%
2017 (partial year)−21.62%

As of October 21, 2026.

YCBD Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$19.19M−$2.04M−10.6%
2024$19.48M−$3.70M−19.0%
2023$24.16M−$22.94M−95.0%
2022$35.40M−$70.08M−198.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$19.19M$11.97M−$2.16M−$2.04M−10.6%
2024$19.48M$12.00M−$3.32M−$3.70M−19.0%
2023$24.16M$14.98M−$9.27M−$22.94M−95.0%
2022$35.40M$22.34M−$17.31M−$70.08M−198.0%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

YCBD Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricYCBDDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.202.100.1x the median
Profit margin−13.80%−8.14%5.7 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

cbdMD, Inc. (YCBD) is capitalised at $4.25M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 42 employees.

YCBD last closed at $0.38 on October 21, 2026. That is −$0.01 (−2.17%) against the previous close. The 52-week range on file runs from $0.33 to $2.56. The latest close sits 14.82% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $19.19M. Against the prior fiscal year total of $19.48M, that is a change of −1.50%. The same year closed with a net loss of $2.04M. Profit margin runs at −13.8%. That is 5.7 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%.

Across the 4 fiscal years on file, revenue moves from $35.40M in 2022 to $19.19M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.2 times revenue. On price-to-sales that is 0.1 times the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.25. Annualized volatility over the trailing 8 years is 121.16%. Over the trailing twelve months the total return is −64.25%. Measured over 5 years, that is −78.16% a year compounded.

Growth & Income

No dividend is on file for YCBD.

The strongest complete calendar year on file is 2020 at +30.53%; the weakest is 2023 at −89.82%. Of the 8 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −71.93%.

Peer Comparison

cbdMD, Inc. (YCBD) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
cbdMD, Inc. YCBD $4.25M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About cbdMD, Inc.

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. It also provides products for dogs and cats, including tinctures, chews, and topicals under the Paw CBD brand name; non-cannabinoid functional ingredients, such as functional mushrooms under the ATRx brand; and hemp-derived solutions under the Herbal Oasis brand. It serves retailers, and health and pet channels through the direct-to-consumer channel, e-commerce platforms, online marketplaces, and wholesale distribution. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is based in Charlotte, North Carolina.

Visit website →